|
| Press Releases |
|
 |
|
| Friday, July 25, 2025 |
|
|
雲頂新耀宣布配售股份 擬集資約15.725億港元 |
| 雲頂新耀有限公司（HKEX1952.HK）是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司，今日宣布以先舊後新配售22,561,000股，集資約15.725億港元，發行股份數占現有股本約6.87%, 占經擴大後的總股數約6.43%。 more info >> |
|
|
云顶新耀宣布配售股份 拟集资约15.725亿港元 |
| 云顶新耀有限公司（HKEX1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布以先旧后新配售22,561,000股，集资约15.725亿港元，发行股份数占现有股本约6.87%, 占经扩大后的总股数约6.43%。 more info >> |
|
| Tuesday, July 15, 2025 |
|
|
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力 |
| 今日雲頂新耀（01952.HK）股價表現亮眼，盤中最高價觸及73.4港元，再創新高。 more info >> |
|
|
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力 |
| 今日云顶新耀（01952.HK）股价表现亮眼，盘中最高价触及73.4港元，再创新高。 more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
|
雲頂新耀發佈AI+mRNA平台新突破 重塑中國mRNA國際競爭格局 |
| 近期，雲頂新耀（HKEX: 1952.HK）在上海成功舉辦「2025雲頂新耀mRNA創新技術平台研發日」，系統展示其自主構建的AI+mRNA平台的最新進展，以及多個管線項目在腫瘤及自身免疫疾病治療中的前沿突破。 more info >> |
|
|
云顶新耀发布AI+mRNA平台新突破 重塑中国mRNA国际竞争格局 |
| 近期，云顶新耀（HKEX: 1952.HK）在上海成功举办“2025云顶新耀mRNA创新技术平台研发日”，系统展示其自主构建的AI+mRNA平台的最新进展，以及多个管线项目在肿瘤及自身免疫疾病治疗中的前沿突破。 more info >> |
|
| Thursday, July 3, 2025 |
|
|
雲頂新耀公佈EVER001-1b/2a期階段性數據 專家看好其作為新一代BTK療法的潛力 |
| 7月1日，雲頂新耀（HKEX: 1952.HK）公佈其自主研發的共價可逆BTK抑制劑EVER001在治療原發性膜性腎病（pMN）的1b/2a期臨床研究中取得最新數據。 more info >> |
|
|
云顶新耀公布EVER001-1b/2a期阶段性数据 专家看好其作为新一代BTK疗法的潜力 |
| 7月1日，云顶新耀（HKEX: 1952.HK）公布其自主研发的共价可逆BTK抑制剂EVER001在治疗原发性膜性肾病（pMN）的1b/2a期临床研究中取得最新数据。 more info >> |
|
| Friday, June 20, 2025 |
|
|
雲頂新耀加速全球佈局 耐賦康(R)與EVER001雙引擎釋放創新藥價值潛力 |
| 近日，天風證券舉辦「雲頂新耀（1952.HK）耐賦康®&EVER001——2025歐洲腎臟協會（ERA）大會數據解讀會」，圍繞公司在ERA大會披露的最新研究成果，深入分析其在慢病治療領域的產品潛力、國際化合作前景及平台型創新價值。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 18:00: JST
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00: JST
|
|
|
日清食品（香港）慈善基金连续第四年支持 香港教育大学精英运动员
Jan 31, 2026 07:21 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 22:30: JST
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 21:30 HKT/SGT
|
|
|
SuperX Commences Production at First Global Supply Center
Jan 30, 2026 19:24 HKT/SGT
|
|
|
Quam Plus Financial Proudly Serves as Gold Sponsor, The 3rd Hong Kong Capital Markets Forum 2026 Successfully Concludes
Jan 30, 2026 19:18 HKT/SGT
|
|
|
From Digitization to AI Computing: Cheche Group Inc. (CCG) Partners with Volkswagen DSSO and Cardif Airstar Insurance to Usher in the "Premium Era" of Advanced Smart Driving Insurance
Jan 30, 2026 18:35 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Fourth Consecutive Year
Jan 30, 2026 18:11 HKT/SGT
|
|
|
日清食品（香港）慈善基金連續第四年支持 香港教育大學精英運動員
Jan 30, 2026 17:57 HKT/SGT
|
|
|
（don't delete）日清食品（香港）慈善基金连续第四年支持 香港教育大学精英运动员
Jan 30, 2026 17:42 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
